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A B S T R A C T  
Objective: To identify the frequency of dyslipidemia in diabetic patients. 
Patients and Methods: A cross sectional study was conducted among the patients visiting Pathology laboratory in 
Pakistan Institute of Medical Sciences (PIMS). After taking informed consent from the patients, a brief history was taken 
from the patients with the help of a questionnaire. Lipid profiles for these patients were analyzed using the same 
samples as of HbA1c to determine diabetic dyslipidemia. 
Results: A total number of 206 diabetic patients were inducted in this study. Out of the total sample, 179 (72.7%) 
respondents were on anti-diabetic therapy alone. About 31 (17.3%) were on antihypertensive therapy along with anti-
diabetic therapy. Only 36 (20.1%) patients were on lipid lowering medication along with anti-diabetic and anti-
hypertensive treatment. Dyslipidemia was more common in patients that were only on anti-diabetic therapy. 
Conclusion: Annual screening for dyslipidemia and management were not practiced according to guidelines for diabetic 
patients. Combination therapy comprising anti-diabetic and anti-dyslipidemia medications should be considered by 
clinicians instead focusing only on diabetes. 
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I n t r o d u c t i o n  
 
In year 2014 global  prevalence for Diabetes was 
estimated to be 9% in young adults.1 About 1.5 million 
deaths in year 2012 were directly because of Diabetes.2  
The relationship between Diabetes, diabetic dyslipidemia 
and Cardio Vascular Diseases(CVS) has been 
established long ago. Vascular diseases have a major 
share in lowering quality of life and death.3 A number of 
risk factors have been determined for coronary artery and 
cardiovascular diseases, among these deranged lipid 
profiles are a major contributor to the  development of 
coronary artery disease.4 Lipoproteins increase is 
associated with significant risk of atherosclerosis.5 Globaly 
dyslipidemia results in 4 million deaths per annum.6 
Dyslipidemia means the derangement in body lipid levels, 
but most of the time dyslipidemia presents as 
hyperlipidemia. Hyperlipidemia may be due to 
hyperlipoprotinemia i.e. Increased levels of Low Density 
Lipoprotein (LDL), hypercholesterolemia or as 
hypertriglyceridemia or may be all combined. These were 
defined according to Fredrickson Classification.7 But 
dyslipidemia may present as hypolipidemia i.e. low levels 
of High Density Lipoproteins (HDL).8 A number of risk  
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factors has been identified that leads to dearrangements 
in body lipids. These include lifestyle, obesity, high insulin 
and a number of other genetic and environmental factors.  
In present situation clinicians are focusing more on 
diagnosis and treatment of diabetes only. Dyslipidemia 
associated with this condition is usually given lesser 
attention by the clinicians. Lipid profiles are not done 
frequently for diabetic patients. In this study we planned 
to identify the frequency of dyslipidemia in diabetic 
patients and to know if the population is taking only anti 
diabetic treatment or a combination with lipid lowering 
drugs. 
P a t i e n t s  a n d  M e t h o d s  
A cross sectional survey was conducted among the 
patients visiting Pathology laboratory in Pakistan Institute 
of Medical Sciences (PIMS), Shaheed Zulfiqar Ali Bhutto 
Medical University (SZAMBU), Islamabad from May, 2016 
to July, 2016 by convenient sampling technique. A study 
sample of 222 patients was obtained using WHO 
calculator taking prevalence 17.5%, confidence level 95% 
and absolute precision of 5%.9 A total 250 diabetic 
patients were inducted in the study. Out of 250, total 4 
patients lost the study follow up and were excluded.  
After induction, patients were divided into three groups. 
Group 1 comprised of patients only on antidiabetic 
therapy. Group 2 comprised of patients receiving 
antihypertensive therapy along with antidiabetic 
medications. Group 3 included patients on lipid lowering 
medication along with antidiabetic and antihypertensive 
therapy. Group 1 Patients were further divided into three 
sub-groups on the basis of their HbA1c levels. Group 1a 
comprised of good glycemic control with normal HbA1c 
levels (HbA1c ≤6.5%), group 1b included patients with 
average glycemic control (HbA1c 6.6-9%) and group 1c 
with poor glycemic control (HbA1c > 9%). All subgroups  
of Group 1 were then considered for lipid profile 
evaluation. Dyslipidemia was defined according to the 
National Cholesterol Education Program Adult Treatment 
Panel (ATP) III. Presence of dyslipidemia was identified 
when LDL ≥ 130mg/dl, HDL <40 mg/dl, TC ≥200 mg/dl 
and triglycerides were ≥150 mg/dl. 
After taking informed consent from the patients, a brief 
history including drug details was taken with the help of a 
questionnaire. Total 3 ml fasting blood sample was taken 
to analyze HbA1c levels. By using the same fasting 
samples lipid profile was also calculated to determine 
diabetic dyslipidemia. Patients with deranged lipid profiles 
were identified and their drug therapy was assessed 
according to the history. Patients were followed by their 
phone numbers. Nominal data was collected and 
analyzed using SPSS version 20.  
R e s u l t s  
Total number of 246 participants included this study. 
Mean age of the respondents was 57.5 ± 15.2 years. 
Mean HbA1c value was 8.7 ± 2.5 %. Male patients were 
132 (53.6%) and females were 114 (46.3%). Out of 246 
diabetic patients, total 179 (72.7%) respondents were in 
group 1 (anti diabetic therapy alone), 31 were in group 2 
(anti diabetic + anti-hypertensive therapy) and 36 were in 
group 3 (anti diabetic+ anti-hypertensive +lipid lowering 
medications). After further sub division of group 1, total 82 
(45.8%) patients were in group 1a (good glycemic 
control), 53 (29.6%) were in group 1b (average glycemic 
control) and 44 (24.5%) patients were in group 1c (poor 
glycemic control) (Figure 1).  
 
Figure 1: Comparison of glycemic control in patients 
only on anti-diabetic therapy (n=179) 
 
In group 1, regarding lipid profile, HDL levels were 
deranged in large number of participants (70.3%). 
Prevalence of other lipid parameters with percentage 
derangements is shown in (Table 1).  
Family history for diabetes and hypertension was found 
positive among 65 (36.3%) of the respondents. Only 48 
(26.8%) had their lipid profile done in the past one year.  
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Lipid parameters were maximally deranged in patients 
having poorly controlled diabetes (Table 2). 
D i s c u s s i o n  
This study was conducted to evaluate the prevalence of 
dyslipidemia in our population along with treatment 
regimens for diabetic patients. The study concluded that 
most of the population is unaware of association between 
Diabetes with dyslipidemia. Only a small population had 
lipid lowering drugs prescribed along with anti-diabetic 
therapy (20.1%). Only anti-diabetic regimen was also 
observed among people of Czech Republic.10 
Dyslipidemia screening practices were not adequate in 
diabetic patients of our study (26.8%). Annual screening 
of diabetics by lipid profiles is the recommended 
guidelines by American Association of Clinical 
Endocrinologists (AACE). 11 
Contrary to this monotherapy approach was prevalent in 
our population. Combination regimens to control 
dyslipidemia was found in very few. A statin should be  
prescribed to a patient of age greater than 40 years with 
diagnosed diabetes.12  Stone et. al. in their guidelines also 
highlighted the use of statin therapy in a patient with 
diabetes and age 40 to 75 years or the LDL > 190 
mg/dl.13 More than 50% of our population had 
uncontrolled Diabetes Mellitus. This is a factor that 
contributes to increased number of complications 
including vascular diseases and atherosclerosis.14 In our 
neighboring country the percentage of uncontrolled 
diabetes exceeds 80% and due to uncontrolled diabetes, 
lipids are more deranged in Indian population.15 TC and 
TGs values of our population (22.9% and 40.7%) were 
more than Chinese population data (16.4% and 7.6%). 16 
Values of these parameters were less when compared to 
Turkish population.17 LDL values for our population was 
far less than Turkish population17 (13.4% versus 36.2%). 
Surprisingly HDL levels of our population were 
significantly reduced (in about 70%). These values did not 
coincide with any of other populations viewed in literature. 
C o n c l u s i o n  
Annual screening for dyslipidemia and management was 
not practiced according to guidelines among diabetic 
patients. Combination therapy comprising anti-diabetic 
and anti-dyslipidemia medications should be considered 
by clinicians instead focusing only on diabetes. Low levels 
of HDL require special attention. Further studies are 
required with large sample size and multi-center surveys 
to identify the causes of such low HDL prevalence among 
our population. 
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